Apr 24, 2019

Why specialty pharmacies matter

Pharmacy benefit managers control a lot of the specialty pharmacy market. Photo: Stan Honda/AFP via Getty Images

Expensive prescription drugs that treat complex conditions often are dispensed through specialty pharmacies, and that "specialty" label is lucrative — especially when those pharmacies are owned by the same companies that manage drug benefits.

Why it matters: State Medicaid programs and private insurance plans are paying steep markups on specialty drugs, according to industry analysts. Those costs are passed on through the taxes and premiums we all pay.

Driving the news: Analysts at research firm 46brooklyn found that Ohio's Medicaid program paid huge markups for generic specialty drugs, benefitting the state's 2 pharmacy benefit managers, CVS Health and OptumRx, at the expense of taxpayers.

  • The most egregious example was imatinib mesylate, the generic version of cancer drug Gleevec. Ohio's Medicaid program paid pharmacies a markup of more than $5,200 for every imatinib mesylate prescription.

How it works: CVS and OptumRx manage drug coverage for Ohio's Medicaid plans. Those plans classify many drugs — including imatinib mesylate — as specialty drugs, meaning they have to be filled through a specialty pharmacy. The catch: CVS and OptumRx own the speciality pharmacies that have to be used.

  • In other words, those companies get to steer high-markup generics toward themselves, and keep the profits.
  • This isn't an anomaly. The big 3 PBMs — CVS, OptumRx and Express Scripts — control more than half of the specialty pharmacy market nationwide. CVS has said its specialty business is a major reason why it's been able to grow revenue.
  • PBMs have faced lawsuits from other specialty pharmacies, which argue that having the PBM and specialty pharmacy under one roof is anticompetitive.

What they're saying: "This isn't just Medicaid," said Antonio Ciaccia, co-founder of 46brooklyn and a part-time pharmacy lobbyist in Ohio. "This extends to the commercial market."

  • Peter Bach, a researcher at Memorial Sloan Kettering who looked at the analysis, said it reminded him of a "60 Minutes" broadcast from last year that explained how Express Scripts distributed specialty drugs.
  • PBMs "create the appearance that they’re trying to save the customer money, but that is not an obligation they face in any way," Bach said.

The other side: CVS, OptumRx and Express Scripts did not make executives available for interviews.

  • A CVS spokesperson said 46brooklyn has "a specific agenda and bias," and "we have no idea how reliable or valid their findings are absent an independent review of their methodology."
  • The Pharmaceutical Care Management Association, the lobbying group for PBMs, emailed a statement, unprompted, disputing the analysis but later acknowledged that none of the data points are wrong.

Yes, but: 46brooklyn's founders do have backgrounds in the pharmacy industry. However, their research uses publicly available federal data, and they post their full methodologies. Ciaccia also responded to PCMA's statement.

Go deeper: States are the new battleground for drug price middlemen

Go deeper

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 2 p.m. ET: 5,453,784 — Total deaths: 345,886 — Total recoveries — 2,191,310Map.
  2. U.S.: Total confirmed cases as of 2 p.m. ET: 1,651,254 — Total deaths: 97,850 — Total recoveries: 366,736 — Total tested: 14,163,915Map.
  3. World: Top Boris Johnson aide defends himself after allegations he broke U.K. lockdown — WHO suspends trial of hydroxychloroquine over safety concerns.
  4. 2020: Trump threatens to move Republican convention from North Carolina — Joe Biden makes first public appearance in two months.
  5. Public health: Officials are urging Americans to wear masks over Memorial Day.
  6. Economy: White House economic adviser Kevin Hassett says it's possible the unemployment rate could still be in double digits by November's election — Charities refocus their efforts to fill gaps left by government.
  7. What should I do? Hydroxychloroquine questions answeredTraveling, asthma, dishes, disinfectants and being contagiousMasks, lending books and self-isolatingExercise, laundry, what counts as soap — Pets, moving and personal healthAnswers about the virus from Axios expertsWhat to know about social distancingHow to minimize your risk.
  8. Other resources: CDC on how to avoid the virus, what to do if you get it, the right mask to wear.

Subscribe to Mike Allen's Axios AM to follow our coronavirus coverage each morning from your inbox.

Updated 52 mins ago - Politics & Policy

Joe Biden makes first public appearance in over two months

Photo: Oliver Douliery/AFP via Getty Images

Former Vice President Joe Biden made his first in-person appearance in over two months on Monday to honor Memorial Day by laying a wreath at a Delaware veterans park, AP reports.

Why it matters: Biden, the Democratic Party's presumptive nominee, has taken the unprecedented step of campaigning from his home during the coronavirus pandemic, ever since canceling a rally in Cleveland on March 10.

WHO temporarily suspends trial of hydroxychloroquine over safety concerns

Photo: Fabrice Coffrini/AFP via Getty Images

The World Health Organization is temporarily pausing tests of the anti-malarial drug hydroxychloroquine as a coronavirus treatment in order to review safety concerns, the agency's director-general Tedros Adhanom Ghebreyesu said Monday.

Why it matters: The decision comes after a retrospective review published in The Lancet found that coronavirus patients who took hydroxychloroquine or its related drug chloroquine were more likely to die or develop an irregular heart rhythm that can lead to sudden cardiac death, compared to those who did nothing.